STARPHARMA HOLD/S (SPHRY) Upgraded to “Buy” at ValuEngine

STARPHARMA HOLD/S (OTCMKTS:SPHRY) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Friday, ValuEngine reports.

Separately, Macquarie initiated coverage on shares of STARPHARMA HOLD/S in a research note on Wednesday, January 16th. They issued an “outperform” rating for the company.

SPHRY opened at $9.62 on Friday. STARPHARMA HOLD/S has a 1 year low of $6.61 and a 1 year high of $11.87.

STARPHARMA HOLD/S Company Profile

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom.

Recommended Story: Price-Sales Ratio

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for STARPHARMA HOLD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STARPHARMA HOLD/S and related companies with MarketBeat.com's FREE daily email newsletter.